CD4 and tuberculosis: Considering loss to follow-up, treatment failure, and death as adverse outcomes, the sensitivity analysis showed that age 55 years or older (aOR 4.24; 95% CI: 1.34–13.43) was correlated with having this composite adverse outcome, whereas CD4 < 100 cells/mm3 at TB treatment start (aOR 2.98; 95% CI: 0.97–9.16) and being treated with an LTR was not (aOR 1.98; 95% CI: 0.77–5.08).